We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Investment Ideas feature highlights: Workday, Energy Transfer and Insulet
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 8, 2023 – Today, Zacks Investment Ideas feature highlights Workday (WDAY - Free Report) , Energy Transfer (ET - Free Report) and Insulet (PODD - Free Report) .
Insider Buys: 3 CEOs Scooping Up Sales
Market participants closely follow insider activity, as the transactions can reflect current sentiment surrounding the future state of business. Of course, investors typically get a confidence boost upon seeing an insider swoop in for a buy.
Insiders are defined as those in the possession of non-public information, commonly executive officers or the board of directors. To little surprise, many strict rules apply to insiders. And they typically have a holding horizon longer than most, a critical aspect to be aware of.
As of late, the CEOs of several companies, including Workday, Energy Transfer and Insulet have acquired shares. What did they see? Let's take a closer look.
Workday
Workday provides enterprise-level software solutions for financial management and human resource domains. Co-CEO Carl Eschenbach purchased roughly 8,700 WDAY shares in late August, with the transaction totaling just under $2.1 million.
The company's latest quarterly results came in better than expected, registering a 15% EPS surprise and a modest revenue beat. In fact, Workday has exceeded the Zacks Consensus EPS Estimate by an average of 15% across its last four releases.
Workday was firing on all cylinders throughout its latest quarter; operating income totaled $36.3 million, up nicely from a loss of -$34.1 million in the comparable period last year. Further, cash flow from operations reached $425 million, well above the $114 million in the year-ago period.
Interestingly enough, WDAY shares have seen bullish activity post-earnings regularly over the last year.
Workday is forecasted to see decent growth, with Zacks Consensus Estimates suggesting nearly 50% higher earnings on 16% higher sales in its current year. And in FY25, expectations allude to an additional 18% earnings growth paired with a 17% sales bump.
Energy Transfer
Energy Transfer owns and operates diversified portfolios of energy assets primarily in the United States. CEO Marshall McCrea III purchased 50,000 ET shares at a total price tag of $682 thousand at the beginning of September.
Income-focused investors could find ET shares attractive, currently yielding a sizable 9.2% annually, well above the Zacks Oils and Energy sector average.
The 200-day simple moving average looks to be a solid place to add ET shares on weakness, as shares have consistently respected the level in past instances.
There were several highlights from its latest earnings release, including the acquisition of Lotus Midstream Operations, expected to expand Energy Transfer's crude pipeline footprint across the Permian Basin.
Insulet
Insulet Corporation is a leading developer, manufacturer, and marketer of the Omnipod Insulin Management System. CEO James Hollingshead purchased 5,550 PODD shares, with the total transaction totaling just over $1 million.
The company has enjoyed positive earnings estimate revisions across the board, reflecting optimism among analysts.
Insulet's growth has been hard to ignore, with 2023 Q2 revenues of $397 million improving 32% from the year-ago period. Impressively, the company has posted double-digit percentage year-over-year revenue growth rates in ten consecutive quarters.
And the growth is slated to continue, with Zacks Consensus Estimates suggesting a sizable earnings jump in its current year on nearly 25% higher revenues.
Insulet raised its FY23 revenue guidance following its latest better-than-expected results, now expecting sales to grow in a bracket of 22% – 25%, nicely above the previous 18% – 22% expected.
Bottom Line
It's easy to understand why investors closely follow insider activity, as it can provide a snapshot of current sentiment surrounding a company's future. An insider buy is undoubtedly a positive, whereas a sell could carry negative undertones in certain situations.
And for those seeking stocks insiders are diving into, all three above have all seen their CEOs step in.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Investment Ideas feature highlights: Workday, Energy Transfer and Insulet
For Immediate Release
Chicago, IL – September 8, 2023 – Today, Zacks Investment Ideas feature highlights Workday (WDAY - Free Report) , Energy Transfer (ET - Free Report) and Insulet (PODD - Free Report) .
Insider Buys: 3 CEOs Scooping Up Sales
Market participants closely follow insider activity, as the transactions can reflect current sentiment surrounding the future state of business. Of course, investors typically get a confidence boost upon seeing an insider swoop in for a buy.
Insiders are defined as those in the possession of non-public information, commonly executive officers or the board of directors. To little surprise, many strict rules apply to insiders. And they typically have a holding horizon longer than most, a critical aspect to be aware of.
As of late, the CEOs of several companies, including Workday, Energy Transfer and Insulet have acquired shares. What did they see? Let's take a closer look.
Workday
Workday provides enterprise-level software solutions for financial management and human resource domains. Co-CEO Carl Eschenbach purchased roughly 8,700 WDAY shares in late August, with the transaction totaling just under $2.1 million.
The company's latest quarterly results came in better than expected, registering a 15% EPS surprise and a modest revenue beat. In fact, Workday has exceeded the Zacks Consensus EPS Estimate by an average of 15% across its last four releases.
Workday was firing on all cylinders throughout its latest quarter; operating income totaled $36.3 million, up nicely from a loss of -$34.1 million in the comparable period last year. Further, cash flow from operations reached $425 million, well above the $114 million in the year-ago period.
Interestingly enough, WDAY shares have seen bullish activity post-earnings regularly over the last year.
Workday is forecasted to see decent growth, with Zacks Consensus Estimates suggesting nearly 50% higher earnings on 16% higher sales in its current year. And in FY25, expectations allude to an additional 18% earnings growth paired with a 17% sales bump.
Energy Transfer
Energy Transfer owns and operates diversified portfolios of energy assets primarily in the United States. CEO Marshall McCrea III purchased 50,000 ET shares at a total price tag of $682 thousand at the beginning of September.
Income-focused investors could find ET shares attractive, currently yielding a sizable 9.2% annually, well above the Zacks Oils and Energy sector average.
The 200-day simple moving average looks to be a solid place to add ET shares on weakness, as shares have consistently respected the level in past instances.
There were several highlights from its latest earnings release, including the acquisition of Lotus Midstream Operations, expected to expand Energy Transfer's crude pipeline footprint across the Permian Basin.
Insulet
Insulet Corporation is a leading developer, manufacturer, and marketer of the Omnipod Insulin Management System. CEO James Hollingshead purchased 5,550 PODD shares, with the total transaction totaling just over $1 million.
The company has enjoyed positive earnings estimate revisions across the board, reflecting optimism among analysts.
Insulet's growth has been hard to ignore, with 2023 Q2 revenues of $397 million improving 32% from the year-ago period. Impressively, the company has posted double-digit percentage year-over-year revenue growth rates in ten consecutive quarters.
And the growth is slated to continue, with Zacks Consensus Estimates suggesting a sizable earnings jump in its current year on nearly 25% higher revenues.
Insulet raised its FY23 revenue guidance following its latest better-than-expected results, now expecting sales to grow in a bracket of 22% – 25%, nicely above the previous 18% – 22% expected.
Bottom Line
It's easy to understand why investors closely follow insider activity, as it can provide a snapshot of current sentiment surrounding a company's future. An insider buy is undoubtedly a positive, whereas a sell could carry negative undertones in certain situations.
And for those seeking stocks insiders are diving into, all three above have all seen their CEOs step in.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.